The study is designed to evaluate how MIV-711 affects biomarkers known to be relevant for measuring bone and cartilage turnover and the therapeutic dose levels to be used in future studies.
Medivir CEO Maris Hartmanis said the study will provide the company with crucial biomarker information reflecting both bone and cartilage turnover.
"Based on this data we will be able to make a fast and informed decision regarding the continued development of MIV-711 to the market," Hartmanis added.
In the study designed to evaluate the safety, tolerability and pharmacokinetics, MIV-711 will be administered as single ascending oral doses to healthy volunteers, followed by repeated once daily doses for seven days.
In addition effect on biomarkers relevant for bone and cartilage degradation will be followed, the company said.
The company expects to reveal the study data in the first quarter of 2013.